N. Yasui

发表

Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects.

K. Otani, S. Kaneko, T. Kondo, 1998, Therapeutic drug monitoring.

Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients.

K. Otani, A. Suzuki, S. Kaneko, 1997, Pharmacogenetics.

Carbamazepine augmentation therapy in three patients with trazodone‐resistant unipolar depression

K. Otani, S. Kaneko, N. Yasui, 1996, International clinical psychopharmacology.

Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice.

K. Otani, A. Suzuki, S. Kaneko, 1999, International clinical psychopharmacology.

Effects of repeated ingestion of grapefruit juice on the single and multiple oral-dose pharmacokinetics and pharmacodynamics of alprazolam

K. Otani, S. Kaneko, T. Kondo, 2000, Psychopharmacology.

Effect of Carbamazepine on the Single Oral Dose Pharmacokinetics of Alprazolam

K. Otani, S. Kaneko, T. Kondo, 1998, Neuropsychopharmacology.

Characteristics and risk factors of acute dystonia in schizophrenic patients treated with nemonapride, a selective dopamine antagonist.

K. Otani, S. Kaneko, T. Kondo, 1999, Journal of clinical psychopharmacology.

Effects of Genetically Determined S–Mephenytoin 4–Hydroxylation Status and Cigarette Smoking on the Single–Dose Pharmacokinetics of Oral Alprazolam

K. Chiba, T. Ishizaki, K. Otani, 1997, Neuropsychopharmacology.

Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity.

K. Chiba, T. Ishizaki, K. Otani, 1997, Therapeutic drug monitoring.

Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol.

K. Otani, A. Suzuki, S. Kaneko, 1997, Therapeutic drug monitoring.

Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam.

S. Kaneko, T. Kondo, N. Yasui, 2004, British journal of clinical pharmacology.

Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite

K. Otani, A. Suzuki, S. Kaneko, 1998, Psychopharmacology.

Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin.

K. Otani, S. Kaneko, T. Kondo, 2000, Journal of clinical psychopharmacology.

Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia.

K. Otani, A. Suzuki, S. Kaneko, 2000, Therapeutic drug monitoring.

Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients

K. Otani, S. Kaneko, G. Tybring, 1998, European Journal of Clinical Pharmacology.

Plasma concentrations of trazodonb and m-chlorophenylpiperazine at steady state can be predicted from those after an initial dose of trazodone

K. Otani, S. Kaneko, T. Kondo, 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.

K. Otani, S. Kaneko, H. Higuchi, 1995, International clinical psychopharmacology.

Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients.

K. Otani, A. Suzuki, S. Kaneko, 1997, Pharmacogenetics.

Effects of the CYP2D6*10 allele on the steady‐state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

K. Otani, A. Suzuki, S. Kaneko, 1999, Clinical pharmacology and therapeutics.

Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine

S. Tsuchida, F. Gonzalez, K. Otani, 1997, Psychopharmacology.

Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine.

K. Otani, A. Suzuki, S. Kaneko, 1997, Therapeutic drug monitoring.

No interaction between desipramine and bromperidol

K. Otani, A. Suzuki, S. Kaneko, 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients

K. Otani, A. Suzuki, S. Kaneko, 1997 .

No relationship between −141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study

K. Otani, A. Suzuki, S. Kaneko, 2001, Psychiatry Research.

Plasma prolactin concentration and psychopathology of schizophrenia

K. Otani, A. Suzuki, S. Kaneko, 1996, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in alprazolam metabolism

T Ishizaki, K Chiba, K. Chiba, 1996, Clinical pharmacology and therapeutics.

Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.

S. Kaneko, N. Yasui, K. Sugawara, 1999, Journal of Pharmaceutical and Biomedical Analysis.

High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection.

S. Kaneko, N. Yasui, T. Ohkubo, 1998, Journal of Chromatography B: Biomedical Sciences and Applications.

High‐performance Liquid Chromatographic Determination of Trazodone and 1‐m‐Chlorophenylpiperazine with Ultraviolet and Electrochemical Detector

N. Yasui, K. Sugawara, T. Ohkubo, 1995, The Journal of pharmacy and pharmacology.

Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene

K. Otani, A. Suzuki, S. Kaneko, 2000, Psychopharmacology.

No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol.

K. Otani, A. Suzuki, S. Kaneko, 1999, Therapeutic drug monitoring.

Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients

K. Otani, S. Kaneko, N. Yasui, 1997, International clinical psychopharmacology.

Prolactin response to bromperidol treatment in schizophrenic patients.

K. Otani, A. Suzuki, S. Kaneko, 1998, Pharmacology & toxicology.

Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol

K. Otani, A. Suzuki, S. Kaneko, 1998, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Interaction between carbamazepine and bromperidol

K. Otani, A. Suzuki, S. Kaneko, 1997, European Journal of Clinical Pharmacology.

Relationship between single oral dose pharmacokinetics of alprazolam and triazolam

K. Otani, S. Kaneko, H. Tasaki, 1997, International clinical psychopharmacology.

Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.

K. Otani, A. Suzuki, S. Kaneko, 1999, Journal of clinical psychopharmacology.

Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients

K. Otani, S. Kaneko, Y. Inoue, 1999, Psychopharmacology.

Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites.

C. Eap, K. Otani, S. Kaneko, 1999, Therapeutic drug monitoring.

Inhibition of Trazodone Metabolism by Thioridazine in Humans

K. Otani, S. Kaneko, T. Kondo, 1995, Therapeutic drug monitoring.

Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam

K. Otani, S. Kaneko, Tadashi Ohkubo, 1998, Psychopharmacology.

Rhabdomyolysis without neuroleptic malignant syndrome induced by additional treatment of risperidone

K. Otani, S. Kaneko, T. Kondo, 1998 .

No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite.

K. Otani, A. Suzuki, S. Kaneko, 1997, Therapeutic drug monitoring.

Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam

S. Kaneko, T. Kondo, N. Yasui, 2022 .

Mechanisms of the development of trazodone withdrawal symptoms.

K. Otani, S. Kaneko, O. Tanaka, 1994, International clinical psychopharmacology.

Prolactin response to nemonapride, a new antipsychotic drug, in schizophrenic patients

K. Otani, A. Suzuki, S. Kaneko, 1997 .

Trazodone treatment increases plasma prolactin concentrations in depressed patients

K. Otani, S. Kaneko, N. Yasui, 1995, International clinical psychopharmacology.